[January 23, 2013]

The Law Firm of Levi & Korsinsky, LLP Notifies Investors of Claims of Breaches of Fiduciary Duty by the Board of MAP Pharmaceuticals Inc. in Connection with the Sale of the Company to Allergan Inc.

Levi & Korsinsky is investigating the Board of Directors of MAP Pharmaceuticals Inc. ("MAP" or the "Company") (NasdaqGS: MAPP) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Allergan Inc. (NYSE: AGN (News - Alert)).

Click here to learn how to join the action: http://zlk.9nl.com/map-pharmaceuticals-mapp/, or call: 877-363-5972. There is no cost or obligation to you.

Under the terms of the transaction, MAP shareholders will receive $25 for each share of MAP stock they own. The transaction ha total approximate value of $958 million. The investigation concerns whether the MAP Board of Directors breached their fiduciary duties to stockholders by failing to adequately shop the Company before entering into this transaction and whether Allergan Inc. is underpaying for MAP, thus unlawfully harming MAP stockholders.

If you own common stock in MAP and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or http://zlk.9nl.com/map-pharmaceuticals-mapp/.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major securities lawsuits and have successfully recovered multimillion-dollar damages awards on behalf of investors. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

[ Back To Technology News's Homepage ]